SFDA approves Qfitlia for bleeding prevention in hemophilia patients

December 18, 2025December 18, 2025

Saudi Gazette reportRIYADH — The Saudi Food and Drug Authority (SFDA) has approved Qfitlia (Fitusiran) for the prevention or reduction of bleeding episodes in adults and adolescents aged 12 and aboveSaudi Gazette reportRIYADH — The Saudi Food and Drug Authority (SFDA) has approved Qfitlia (Fitusiran) for the prevention or reduction of bleeding episodes in adults and adolescents aged 12 and above

Previous PostAlUla Development Company appoints John Pagano as managing directorNext PostOver 1,000 Were Killed in Attack on Camp in Darfur, Sudan, U.N. Says